KYTHERA Biopharmaceuticals, Inc. announced the pricing of its initial public offering of 4,400,000 shares of its common stock at a price to the public of $16.00 per share.
The shares of KYTHERA’s common stock will trade on the NASDAQ Global Select Market under the symbol "KYTH." All of the shares of common stock are being offered by KYTHERA. In addition, KYTHERA has granted the underwriters a 30-day option to purchase up to an additional 660,000 shares of common stock to cover over-allotments, if any.
The offering is expected to close on October 16, 2012, subject to customary closing conditions.
J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Leerink Swann LLC is acting as lead co-manager and Lazard Capital Markets LLC is acting as co-manager.
KYTHERA’s product candidate, ATX-101, is an injectable drug currently in Phase III clinical development for the reduction of submental fat.
[Source: KYTHERA news release]